Developing innovative products through novel strategies for infectious diseases.
With a focus on understanding and overcoming resistance mechanisms, we will make prominent, sustainable improvements in patient care across both inpatient and outpatient settings.
Our team has deep expertise in the discovery, development, and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance.
The Unmet Need
Important lessons from COVID-19 about untreatable infectious diseases
The COVID-19 pandemic reminds us how an untreatable infectious disease can spread quickly, overwhelm health care systems, and result in patient morbidity and mortality that was unthinkable to many.
While there is hope in innovation of new treatment and vaccines, we now understand what it is like to have untreatable infections, or how mutations leading to drug resistance can reverse gains from new therapies. Antimicrobial drug resistance (AMR) has been a slowly moving pandemic with similarities but important differences from COVID-19. The difference is that society has enjoyed the benefits of active antibiotics to treat bacterial infections but is now losing them.